Literature DB >> 8960718

Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria.

M S Mega1, D L Masterman, D F Benson, H V Vinters, U Tomiyasu, A H Craig, D J Foti, D Kaufer, D W Scharre, L Fairbanks, J L Cummings.   

Abstract

Clinical criteria for dementia with Lewy bodies (DLB) have been proposed, but their formulation, reliability, and validity require further study. Pathologic criteria for DLB are also undergoing evolution. Two studies were conducted with the goal of identifying the components of these evolving criteria that may benefit from further refinement; one study evaluated the components of the clinical criteria and another study operationalized the pathologic criteria for DLB. Twenty-four patients with a premorbid diagnosis of probable or possible Alzheimer's disease (AD) (n = 18), Parkinson's disease (PD) (n = 5), or progressive supranuclear palsy (PSP) (n = 1) were studied. Inter-rater reliability and validity of the clinical criteria were determined by a retrospective chart review, done by five neurologists, and a blinded pathologic evaluation. The Consortium on dementia with Lewy bodies (CDLB) pathologic criteria were operationalized to compare past criteria and test the validity of the evolving clinical criteria on the dementia patients. Three or more cortical fields (at 250 x magnification) with many (four or more) Lewy bodies (LBs) on ubiquitin immunoreactive sections were required to meet the CDLB neocortical score of > 6. Fifteen of the AD patients had at least one LB in a cortical section, four had many LBs, while three had no LBs; all patients with movement disorder had at least one LB in a cortical section. The sensitivity/specificity ratio of the CDLB probable DLB clinical criteria based upon many LBs being present was 75%/79%. Reformulated clinical criteria that require the presence of extrapyramidal signs significantly predicted those patients with many LBs versus those with few or no LBs (chi 2 = 5.48, p = 0.02) and increased clinical specificity to 100%. This preliminary study identifies components of the evolving clinical and pathologic criteria for DLB that require further refinement.

Entities:  

Mesh:

Year:  1996        PMID: 8960718     DOI: 10.1212/wnl.47.6.1403

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

Review 1.  Neuropsychiatric aspects of Alzheimer's disease.

Authors:  C Ballard; M Walker
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Did Don Quixote have Lewy body disease?

Authors:  P J García Ruiz; L Gulliksen
Journal:  J R Soc Med       Date:  1999-04       Impact factor: 5.344

Review 3.  Lewy bodies and dementia.

Authors:  D Galasko
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

4.  Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older.

Authors:  T Rahkonen; U Eloniemi-Sulkava; S Rissanen; A Vatanen; P Viramo; R Sulkava
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

5.  Assessing Fluctuating Cognition in Dementia Diagnosis: Interrater Reliability of the Clinician Assessment of Fluctuation.

Authors:  Kathleen Van Dyk; Stephanie Towns; Oksana Tatarina; Philip Yeung; Jhedy Dorrejo; Laura B Zahodne; Yaakov Stern
Journal:  Am J Alzheimers Dis Other Demen       Date:  2015-09-03       Impact factor: 2.035

6.  Sleepiness and Unintended Sleep in Parkinson's Disease.

Authors:  David B. Rye
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 7.  Dementia with Lewy bodies. Review of diagnosis and pharmacologic management.

Authors:  Christopher Frank
Journal:  Can Fam Physician       Date:  2003-10       Impact factor: 3.275

8.  Incidence of dementia with Lewy bodies and Parkinson disease dementia.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; Bradley F Boeve; J Eric Ahlskog; Walter A Rocca
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

9.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand.

Authors:  Z Walker; D C Costa; R W H Walker; K Shaw; S Gacinovic; T Stevens; G Livingston; P Ince; I G McKeith; C L E Katona
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

10.  Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype.

Authors:  James B Leverenz; Mark A Fishel; Elaine R Peskind; Thomas J Montine; David Nochlin; Ellen Steinbart; Murray A Raskind; Gerard D Schellenberg; Thomas D Bird; Debby Tsuang
Journal:  Arch Neurol       Date:  2006-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.